Brokerages Expect Audentes Therapeutics Inc (BOLD) Will Announce Earnings of -$0.88 Per Share

Wall Street analysts forecast that Audentes Therapeutics Inc (NASDAQ:BOLD) will report earnings per share (EPS) of ($0.88) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Audentes Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.93) and the highest estimate coming in at ($0.79). Audentes Therapeutics also reported earnings per share of ($0.88) in the same quarter last year. The business is expected to issue its next earnings results on Tuesday, November 13th.

On average, analysts expect that Audentes Therapeutics will report full year earnings of ($3.32) per share for the current fiscal year, with EPS estimates ranging from ($3.50) to ($2.82). For the next financial year, analysts anticipate that the business will post earnings of ($3.74) per share, with EPS estimates ranging from ($4.59) to ($3.01). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Audentes Therapeutics.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.07).

A number of brokerages have issued reports on BOLD. Zacks Investment Research downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 9th. Mizuho upgraded Audentes Therapeutics from a “neutral” rating to a “buy” rating and set a $26.00 price objective on the stock in a research report on Wednesday, August 8th. Raymond James restated a “hold” rating on shares of Audentes Therapeutics in a research report on Wednesday, August 8th. BidaskClub downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. Finally, ValuEngine downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $35.45.

In other news, VP Suyash Prasad sold 10,000 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $36.88, for a total value of $368,800.00. Following the sale, the vice president now directly owns 100 shares in the company, valued at $3,688. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Louis G. Lange sold 33,000 shares of the stock in a transaction that occurred on Monday, September 24th. The stock was sold at an average price of $37.38, for a total value of $1,233,540.00. Following the completion of the sale, the director now owns 365,999 shares in the company, valued at $13,681,042.62. The disclosure for this sale can be found here. Over the last quarter, insiders sold 77,039 shares of company stock worth $2,925,260. Company insiders own 6.60% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of BOLD. Redmile Group LLC raised its holdings in shares of Audentes Therapeutics by 70.3% in the second quarter. Redmile Group LLC now owns 2,228,656 shares of the biotechnology company’s stock worth $85,157,000 after buying an additional 920,130 shares during the period. BlackRock Inc. raised its holdings in shares of Audentes Therapeutics by 44.3% in the first quarter. BlackRock Inc. now owns 1,960,404 shares of the biotechnology company’s stock worth $58,910,000 after buying an additional 601,906 shares during the period. Partner Fund Management L.P. purchased a new stake in shares of Audentes Therapeutics in the second quarter worth approximately $16,254,000. Wells Fargo & Company MN raised its holdings in shares of Audentes Therapeutics by 803.8% in the first quarter. Wells Fargo & Company MN now owns 307,537 shares of the biotechnology company’s stock worth $9,242,000 after buying an additional 273,511 shares during the period. Finally, Nexthera Capital LP purchased a new stake in shares of Audentes Therapeutics in the second quarter worth approximately $9,228,000. Hedge funds and other institutional investors own 96.74% of the company’s stock.

BOLD stock traded up $0.56 during midday trading on Friday, reaching $27.69. 1,699,736 shares of the company traded hands, compared to its average volume of 424,443. Audentes Therapeutics has a 52-week low of $24.51 and a 52-week high of $46.18. The company has a market cap of $1.48 billion, a PE ratio of -8.14 and a beta of 0.73.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: Insider Trading – What You Need to Know

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply